PIK3CA and rhabdomyosarcoma: Our results demonstrated that in addition to PI3K p110α, β and γ isoforms, rhabdomyosarcoma cell lines also expressed PI3K p110δ and that targeting this isoform in conjunction with p110α could represent a novel pharmacological strategy to be pursued.